The Preliminary Study On Effect Of Targeting Drugs On Human Non-small Cell Lung Cancer A549 Cells In Vitro And Quantification Of Iodine With Gemstone Spectral Imaging(GSI)

Objective To synthesize the drug with A549 cell targeted and to analyse the inhibition effect of targeting drug on A549 cell in vitro and difference of CT value in different concentrations of drugs.Exploring targeting drug on human non-small cell lung cancer A549 cells in vitro and quantification of iodine with gemstone spectral imaging(GSI).Methods In the first part,Synthesis of small iodine-containing drugs with cytotoxicity targeting A549 cells.A549 cells were treated in vitro with targeting drugs and gefitinib at a concentration gradient of 2.5?5?10?20?40?mol/L.Their proliferation effects were analyzed by the thiazolyl blue(MTT)assay.In the second part,targeting drugs and gefitinib at a concentration gradient of 0?1.87?3.75?7.5?15?30mmol/L underwent GE HD750 CT with GSI mode.Analyzing the inhibition rate of two kinds of drug cell proliferation,comparing the relation and discrepancy between measured iodine concentrations and real iodine concentrations.Results In the first part,Targeting drugs and gefitinib induced a dose-and timeindependent growth inhibition by MTT.When the concentration was more than10?mol/L,the inhibitory rate of targeting drugs was higher than that of gefitinib(p<0.05).In the second part,in a certain range of concentration,The CT value and iodine concentration of targeting drugs were significantly higher than that of gefitinib(p<0.05).The measured concentrations of targeting drugs were obviously correlated to the real concentrations(r=0.998)without significant difference between these two values(p>0.05).Conclusion The targeting drug has good inhibitory effect on A549 cells in vitro.The high CT value of targeting drugs is good for CT shows.GSI of spectral CT is a reliable method to quantify iodine of the targeting drugs.This contrast agent which could has lung cancer targeting is conducive to diagnosis of early-stage cancer and treatment of lung cancer.